Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 31, 2020
Distillery Therapeutics
T cell-specific targeting of KCNA3 for lupus nephritis
DISEASE CATEGORY: Autoimmune disease
INDICATION: Lupus Lipid nanoparticle-based T-cell specific inhibition of the potassium channel KCNA3 could treat lupus nephritis. The nanoparticles contain an
INDICATION: Lupus Lipid nanoparticle-based T-cell specific inhibition of the potassium channel KCNA3 could treat lupus nephritis. The nanoparticles contain an
BioCentury | Jun 4, 2019
Financial News
June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more
BioCentury | Feb 2, 2018
Product R&D
It’s the assay...
How Genentech redesigned a discovery assay to find a specific Nav1.7 blocker
BioCentury | May 11, 2015
Product Development
Check your effectors
Phase Ib data suggest Kineta's Kv1.3 blocker may quell autoimmune flares
BioCentury | Apr 16, 2015
Product R&D
Antagonizing psoriasis
AnaptysBio is developing an IL-36R antagonist for orphan psoriasis indication
Items per page:
1 - 10 of 28